GlaxoSmithKline to buy Biotene for $170 million

GlaxoSmithKline (GSK) Consumer Healthcare will purchase Biotene, a leading dry mouth treatment, from Laclede for $170 million, the company announced. The transaction is subject to regulatory review by competition authorities in the U.S. and Europe, and is expected to be complete by early 2009.

"The acquisition of Biotene extends our portfolio in therapeutic oral healthcare to include a proven treatment for dry mouth," said John Clarke, president of GSK Consumer Healthcare. "This opportunity leverages our global capability with dental and medical professionals, and is a further step toward our goal in GSK of building and growing a diversified healthcare business."

Biotene is the world's leading dentist and hygienist-recommended dry mouth product, with global sales of $50 million in 2007, according to the company. Approximately 65% of the brand's current sales are in the U.S. The Biotene brand includes mouthwash, toothpaste, gel, spray, and gum formulations.

Biotene joins GlaxoSmithKline's portfolio of oral healthcare products, which include Aquafresh, Binaca, Polident, PoliGrip, and Sensodyne.